The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1724
March 17, 2025
View Complete Issue         Table of Contents 2019 
Acoramidis (Attruby) for Transthyretin Amyloid Cardiomyopathy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Acoramidis (Attruby) for Transthyretin Amyloid Cardiomyopathy
March 17, 2025 (Issue: 1724)
The FDA has approved acoramidis (Attruby – BridgeBio), an oral transthyretin stabilizer, to reduce cardiovascular-related hospitalization and cardiovascular death in adults with wild-type or variant (hereditary) transthyretin amyloid...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Acoramidis (Attruby) for Transthyretin Amyloid Cardiomyopathy
Article code: 1724c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.